{"product_id":"glp-1-receptor-agonists-how-they-work-and-what-they-can-treat","title":"GLP-1 Receptor Agonists: How They Work and What They Can Treat","description":"\u003cp\u003eThis review article explains how the glucagon-like peptide-1 (GLP-1) receptor works and how GLP-1-based medications have developed over four decades. It traces the journey from the discovery of the GLP-1 hormone in the 1980s to modern drugs like semaglutide and tirzepatide. It describes how these medications act on the nervous, cardiovascular, musculoskeletal, and digestive systems. The authors report that GLP-1 receptor agonists (GLP-1RAs) show benefits beyond blood sugar control. These benefits include weight loss, heart protection, and possible effects in fatty liver disease, neurodegenerative diseases, and inflammation. The article also compares the main GLP-1RA medications, their dosing, their side effects, and the future direction of research toward longer-acting and oral formulations.\u003c\/p\u003e\n\n\u003ch1\u003eGLP-1 Receptor Agonists: How They Work and What They Can Treat\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#history\"\u003eThe History and Milestones of GLP-1 Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#glp1\"\u003eWhat Is GLP-1?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#glp1r\"\u003eWhat Is the GLP-1 Receptor (GLP-1R)?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#glp1ras\"\u003eWhat Are GLP-1 Receptor Agonists (GLP-1RAs)?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#development\"\u003eHow GLP-1RAs Were Developed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#current\"\u003eCurrent GLP-1RA Medications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#comparison\"\u003eComparing GLP-1RA Medications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sideeffects\"\u003eSide Effects and Safety\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#individual\"\u003eIndividual GLP-1RA Medications in Detail\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eGLP-1 receptor agonists mimic the hormone GLP-1, lowering blood sugar without increasing the risk of dangerously low blood sugar.\u003c\/li\u003e\n\u003cli\u003eThey can reduce body weight by suppressing appetite and reducing energy intake, with newer dual and triple agonists showing stronger effects in trials.\u003c\/li\u003e\n\u003cli\u003eCommon side effects include nausea, vomiting, diarrhea, and injection site reactions; these are often mild and improve over time.\u003c\/li\u003e\n\u003cli\u003eResearch suggests benefits for heart failure, atherosclerosis, and hypertension, but findings come from various studies and individual results may differ.\u003c\/li\u003e\n\u003cli\u003eMany potential benefits for neurodegenerative and inflammatory conditions are still being investigated and are not yet proven treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eIn recent years, the GLP-1 receptor and its agonists have attracted widespread attention in the medical community. The GLP-1 receptor (GLP-1R) is a core member of the G protein-coupled receptor (GPCR) family. GPCRs are a large group of proteins on cell surfaces that receive signals from outside the cell. GLP-1R is widely present on the surfaces of many cell types in the human body.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1R binds specifically to the key hormone GLP-1. Through this binding, GLP-1R regulates blood glucose (sugar) levels and lipid (fat) metabolism. This receptor and its agonists hold significant therapeutic potential. They are reshaping treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1 is a peptide (a short chain of amino acids) produced by the cleavage of proglucagon. It is mainly synthesized in three places: L-cells in the intestinal mucosa, alpha-cells in the pancreatic islet, and neurons in the nucleus of the solitary tract. GLP-1 receptor agonists (GLP-1RAs) mimic the action of the body's own GLP-1. By activating GLP-1R, these drugs enhance insulin secretion, inhibit glucagon release, delay gastric emptying, and reduce food intake through central appetite suppression.\u003c\/p\u003e\n\n\u003cp\u003eThese mechanisms make GLP-1RAs powerful tools for controlling blood glucose and improving metabolic syndrome. Metabolic syndrome is a cluster of conditions that includes high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. Furthermore, the multifaceted mechanisms of action suggest potential applications beyond traditional metabolic disorders.\u003c\/p\u003e\n\n\u003cp\u003eFrom the discovery of the GLP-1 fragment GLP-1(7-37) to the development of more stable and long-acting GLP-1 analogs, these milestones represent significant breakthroughs in the medical field. For example, the success of exenatide spurred the development of potent GLP-1 analogs such as liraglutide and semaglutide. It also unveiled the vast potential of GLP-1RAs in treating various systemic diseases.\u003c\/p\u003e\n\n\u003cp\u003eThe applications of GLP-1RAs extend far beyond diabetes management. Researchers have studied GLP-1RAs in musculoskeletal inflammation, obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, and various cancers. In the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD), GLP-1RAs have shown potential in slowing disease progression. Their anti-inflammatory properties offer new hope for conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), and cardiovascular diseases.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1RAs have also been found to significantly reduce the risks of heart failure, atherosclerosis (AS, hardening of the arteries), and hypertension (high blood pressure). This highlights their broad therapeutic potential. As new indications continue to be developed, GLP-1 drugs demonstrate immense potential in the medical field.\u003c\/p\u003e\n\n\u003cp\u003eThe future of GLP-1RA therapy is promising. Researchers are developing more efficient formulations, such as long-acting and oral versions, to improve patient compliance and outcomes. With increasing clinical evidence, GLP-1RAs are set to become essential in treating complex and chronic diseases. They offer significant health benefits and address unmet medical needs, thus enhancing patient quality of life.\u003c\/p\u003e\n\n\u003ch2 id=\"history\"\u003eThe History and Milestones of GLP-1 Research\u003c\/h2\u003e\n\n\u003cp\u003eThe story of GLP-1 research began in 1979. Richard Goodman found that anglerfish are an ideal source for pancreatic mRNA because their cells are concentrated. mRNA is a molecule that carries instructions for making proteins. Goodman extracted mRNA, spliced anglerfish DNA into bacteria, and used radioactive probes to find the somatostatin gene.\u003c\/p\u003e\n\n\u003cp\u003eIn 1982, Goodman's team published a paper in the Proceedings of the National Academy of Sciences (PNAS). The paper revealed that the glucagon precursor gene actually encodes three peptides: glucagon and two new hormones expressed in the intestine.\u003c\/p\u003e\n\n\u003cp\u003eA year later, a research team led by Graeme Bell from Chiron Corporation published two papers in the journal Nature. They cloned and sequenced the preproglucagon gene. This work led to the discovery of GLP-1 and GLP-2 hormones.\u003c\/p\u003e\n\n\u003cp\u003eThe focus then shifted to GLP-1. In 1983, Svetlana Mojsov identified its insulin-stimulating fragment, GLP-1(7-37). This was inspired by prior GIP (glucose-dependent insulinotropic polypeptide) research. That earlier research highlighted that besides GIP, other substances in the intestine also stimulate insulin secretion. This finding was later combined with research by Joel Habener and jointly published in the Journal of Clinical Investigation (JCI).\u003c\/p\u003e\n\n\u003cp\u003eThe team of Jens Juul Holst at the University of Copenhagen in Denmark published a report in FEBS Letters. They reached the same conclusion in January 1987. In December 1987, Stephen Bloom's team confirmed in a Lancet paper that GLP-1(7-36) is a human intestinal hormone. This hormone stimulates insulin production in the pancreas and lowers blood sugar.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1, used for treating diabetes, is quickly broken down in the body. It requires high doses that can cause side effects like nausea. This led to the development of new drugs similar to GLP-1 but with a longer-lasting effect.\u003c\/p\u003e\n\n\u003cp\u003eJohn Eng marked a significant breakthrough. He isolated exendin-4, a peptide from the Gila monster's venom. Exendin-4 is structurally similar to human GLP-1 but more stable. GLP-1 is degraded in the bloodstream in less than a minute. In contrast, exendin-4, which consists of 39 amino acids, could last for more than two hours. This work was eventually published in the Journal of Biological Chemistry (JBC) in August 1991.\u003c\/p\u003e\n\n\u003cp\u003eIn the early 1990s, John Eng's team identified a potential diabetes treatment in exendin-4. However, it initially lacked attention and funding for development. Eng personally secured a patent and partnered with Amylin. This partnership led to the FDA-approved diabetes drug exenatide in 2005, the first GLP-1 analog.\u003c\/p\u003e\n\n\u003cp\u003eThis sparked further advancements, including Novo Nordisk's development of more potent analogs like liraglutide and semaglutide. Semaglutide achieved over $12 billion in sales by 2022. The journey began in the 1980s with research on Gila monster venom. It culminated in the discovery of exendin-4, a stable and effective peptide for treating diabetes.\u003c\/p\u003e\n\n\u003cp\u003eIn July 2009, researchers published a paper in Nature Chemical Biology. They reported for the first time that dual agonists targeting GLP-1R and glucagon receptor (GCGR) had a better weight loss effect. This marked a significant advancement in obesity treatment research, especially in combining multiple drug targets.\u003c\/p\u003e\n\n\u003cp\u003eMatthias Tschöp and Richard DiMarchi developed the first dual and triple agonist weight loss drugs. Eli Lilly and Company is currently researching a dual agonist called tirzepatide. Tirzepatide has outperformed semaglutide in phase 3 clinical trials. Additionally, their under-development triple agonist, retatrutide, has shown unprecedented weight loss effects in phase 2 clinical trials.\u003c\/p\u003e\n\n\u003cp\u003eMatthias Tschöp and his team discovered that dual agonists targeting both GLP-1 and GIP receptors (GIPR) are more effective in treating diabetes than those targeting only GLP-1R. These dual agonists were found to reduce blood sugar and increase insulin secretion in mice, monkeys, and humans. Subsequently, they investigated a triple agonist capable of simultaneously targeting the GLP-1R, the GCGR, and the GIPR. In December 2014, they published a paper in Nature Medicine. The paper showed that the triple agonist's weight loss effects in mice exceeded those of the dual agonists.\u003c\/p\u003e\n\n\u003cp\u003eThe figure in the original article illustrates the growth of medical publications on GLP-1 and GLP-1RAs from 1978 to 2022. It shows three layered area graphs: research on GLP-1 (red area), GLP-1RAs (blue area), and clinical trials (green area). Key milestones are annotated on the timeline. These milestones include the identification of GLP-1 and GLP-2 through gene sequencing in 1983. These milestones also include the extraction of exendin-4 from Gila monster venom in 1991. These milestones also include the first FDA approval of a GLP-1 analog, exenatide, in 2005. Liraglutide's clinical trials began in 2000, and the drug received FDA approval in 2010. The number of publications increased steeply from 2000 onwards. The peak in 2022 corresponds to GLP-1 drug sales hitting $22 billion. The peak also corresponds to the FDA approval of semaglutide in 2021. The peak also corresponds to the start of the first clinical trial for an oral diabetes drug based on GLP-1 in the same year.\u003c\/p\u003e\n\n\u003ch2 id=\"glp1\"\u003eWhat Is GLP-1?\u003c\/h2\u003e\n\n\u003cp\u003eGLP-1 is a peptide hormone generated through the enzymatic breakdown of proglucagon. It is synthesized in L-cells located in the intestinal mucosa, alpha-cells found in the pancreatic islet, and neurons residing in the nucleus of the solitary tract.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1 is an endocrine hormone. It is secreted by enteroendocrine L-cells located in the distal jejunum, ileum, and colon. These cells release GLP-1 in response to nutrient ingestion and neuroendocrine stimulation. GLP-1 originates from the preproglucagon precursor. This precursor undergoes enzymatic processing within intestinal L-cells. The processing ultimately gives rise to GLP-1(1-37) and GLP-1(7-36) amide or GLP-1(7-37) peptide variants.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1 is an incretin hormone. Incretin hormones play a pivotal role in the careful control of human blood glucose levels. However, its duration of action is rather short-lived. GLP-1 lasts a mere 1 to 2 minutes within the circulatory system under typical physiological conditions. Subsequently, GLP-1 undergoes enzymatic degradation facilitated by dipeptidyl peptidase IV (DPP-4). This degradation leads to the loss of its biological efficacy.\u003c\/p\u003e\n\n\u003ch2 id=\"glp1r\"\u003eWhat Is the GLP-1 Receptor (GLP-1R)?\u003c\/h2\u003e\n\n\u003cp\u003eGLP-1R is a member of the GPCR family. It exhibits specific affinity for GLP-1. GLP-1R predominantly localizes to the cellular membrane of diverse cell types throughout the human body.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1R is present beyond the confines of the pancreas. It extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.\u003c\/p\u003e\n\n\u003cp\u003eThe phenotype (observable characteristics) observed after GLP-1R knockout (KO) includes various physiological and metabolic changes. A knockout is an experimental technique where a gene is removed or inactivated. GLP-1R plays a role in the central nervous system (CNS) regulation of appetite. GLP-1R KO can lead to increased appetite, contributing to weight gain.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1R is involved in regulating both insulin and glucagon secretion. Its knockout can impair pancreatic function, thereby affecting the balance of these hormones and glucose homeostasis. GLP-1R is expressed in the cardiovascular system, and its knockout has implications for cardiovascular function. GLP-1R is present in the CNS, and its absence might contribute to alterations in behavior, mood, or cognitive function.\u003c\/p\u003e\n\n\u003ch2 id=\"glp1ras\"\u003eWhat Are GLP-1 Receptor Agonists (GLP-1RAs)?\u003c\/h2\u003e\n\n\u003cp\u003eGLP-1RAs result from intricate structural modifications to GLP-1. These modifications enable GLP-1RAs to not only replicate the pharmacological functions of GLP-1 but also impede its hydrolysis (breakdown) by DPP-4. This extends the drug's half-life. A half-life is the time it takes for half of the drug to be eliminated from the body.\u003c\/p\u003e\n\n\u003cp\u003eThese synthetic protein preparations exhibit partial or complete amino acid sequence homology with endogenous GLP-1. Homology means similarity in structure. This similarity renders GLP-1RAs resistant to degradation, resulting in a prolonged half-life and heightened biological activity.\u003c\/p\u003e\n\n\u003cp\u003eBy emulating the biological activity of natural GLP-1, GLP-1RAs effectively fulfill the role of GLP-1. They effectively lower blood glucose levels without increasing the risk of hypoglycemia (dangerously low blood sugar). They also demonstrate favorable safety profiles.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents. These agents are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients. They potentially hold promise in addressing other medical conditions. As researchers dive deeper into their multifaceted properties, these medications exhibit the potential to offer therapeutic benefits across a spectrum of diseases in human populations.\u003c\/p\u003e\n\n\u003ch2 id=\"development\"\u003eHow GLP-1RAs Were Developed\u003c\/h2\u003e\n\n\u003cp\u003eThe Gila monster lives in the deserts of the Americas. It can eat up to half its own body weight in one sitting. However, its blood sugar remains stable, and its metabolic system runs smoothly despite this large amount of food.\u003c\/p\u003e\n\n\u003cp\u003eIn 1992, Dr. John Eng discovered an exopeptide in the saliva of the Gila monster, which he named exendin-4. Dr. Eng found that exenatide is an analog of human GLP-1RA, with 53% homology to human GLP-1RA. Exenatide can stimulate human insulin secretion and regulate blood glucose levels in the body. This hormone is not readily degraded by DPP-4 in the human body and can act for 12 hours or longer.\u003c\/p\u003e\n\n\u003cp\u003eIn 2005, exenatide was approved by the U.S. Food and Drug Administration (FDA) for use in treating T2DM. Thus began the competition between various GLP-1RAs.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1RAs are being developed to be more similar to the natural GLP-1 hormone found in the human body. This is achieved by replacing and modifying specific amino acids in human GLP-1. By doing so, the resulting product has a higher similarity or homology to the amino acid sequence of human GLP-1.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, efforts are being made to extend the duration of action of GLP-1RAs. Currently, some GLP-1RAs require daily injections, which can be inconvenient for patients. Therefore, researchers are working toward developing formulations that can be administered once a week. These formulations provide a longer-lasting effect and reduce the frequency of injections.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, there is a focus on developing GLP-1RAs that can be taken orally without the need for injections. This oral preparation would offer a more convenient and comfortable option for patients. It could potentially lead to better treatment compliance.\u003c\/p\u003e\n\n\u003cp\u003eOverall, the future research direction of GLP-1RAs involves making them more similar to those in the human body. The future research direction also involves extending their duration of action. The future research direction also involves creating oral formulations for easier administration. These advancements aim to improve patient experience, compliance, and treatment outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"current\"\u003eCurrent GLP-1RA Medications\u003c\/h2\u003e\n\n\u003cp\u003eGLP-1RAs are synthetic protein preparations that have partial or complete amino acid sequence homology with GLP-1 found in the body. They are not easily degraded, have longer half-lives, and have stronger biological activity. They can play the role of GLP-1.\u003c\/p\u003e\n\n\u003cp\u003eGLP-1RA is primarily used for the treatment of T2DM. It works by mimicking the action of the naturally occurring hormone GLP-1, which is released by the intestines in response to food intake. GLP-1 helps regulate blood sugar levels in three main ways:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eStimulating the release of insulin\u003c\/li\u003e\n  \u003cli\u003eSuppressing glucagon secretion (glucagon raises blood sugar levels)\u003c\/li\u003e\n  \u003cli\u003eSlowing the rate at which the stomach empties, leading to a feeling of fullness and reduced appetite\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn addition to its use in diabetes management, GLP-1RA has also shown potential in other areas of research. Studies have explored its effects on weight loss, NAFLD, and neurodegenerative diseases such as AD. Furthermore, GLP-1RA has been investigated for its potential to reduce the risk of cardiovascular events in patients with or without diabetes.\u003c\/p\u003e\n\n\u003cp\u003eLike any medication, GLP-1RAs may have side effects. These include nausea, vomiting, diarrhea, and injection site reactions. These side effects are often mild and tend to improve over time. Rare but serious side effects may include pancreatitis (inflammation of the pancreas) and allergic reactions.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes the GLP-1RA medications used in type 2 diabetes mellitus, including their approval dates, brand names, half-lives, doses, and clinical trial focus:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExenatide (Byetta)\u003c\/strong\u003e — approved 2005; half-life 2.4 hours; dose 5 or 10 micrograms twice daily by subcutaneous injection; clinical trial focus: Parkinson's disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiraglutide (Victoza\/Saxenda)\u003c\/strong\u003e — approved 2010; half-life 11 to 13 hours; dose 0.6 mg and 1.2 or 1.8 mg once daily by subcutaneous injection; clinical trial focus: cardiovascular disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLixisenatide (Adlyxin in the U.S. \/ Lyxumia in the EU)\u003c\/strong\u003e — approved 2013; half-life 2 to 4 hours; dose 10 micrograms then 20 micrograms once daily by subcutaneous injection; clinical trial focus: early Parkinson's disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlbiglutide (Tanzeum)\u003c\/strong\u003e — approved 2014; half-life 6 to 8 hours; dose 30 or 50 mg once weekly by subcutaneous injection; clinical trial focus: cardiovascular disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDulaglutide (Trulicity)\u003c\/strong\u003e — approved 2014; half-life 108 to 112 hours; dose 0.75 or 1.5 mg once weekly by subcutaneous injection; clinical trial focus: type 2 diabetes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExenatide extended-release (BYDUREON BCise)\u003c\/strong\u003e — approved 2017; half-life 2 weeks; dose 2 mg once weekly by subcutaneous injection; clinical trial focus: type 1 diabetes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSemaglutide (Ozempic)\u003c\/strong\u003e — approved 2017; half-life 6 to 7 days; dose 0.25 mg then 0.5 mg once weekly by subcutaneous injection; clinical trial focus: obesity-related heart failure\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOral semaglutide (Rybelsus)\u003c\/strong\u003e — approved 2019; half-life 24 hours; dose 3 mg then 7 mg once daily by mouth; clinical trial focus: type 2 diabetes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn this table, \"pen\" refers to the injection form, and \"po\" means orally. The abbreviations are: q.d. (once daily), q.w. (once weekly), b.i.d. (twice daily), t.i.d. (three times daily), SC (subcutaneous administration), w (week), and po (orally). The date refers to the date when the drug was approved by the U.S. Food and Drug Administration (FDA). Clinical trial focus describes the main disease targeted in recent clinical trials.\u003c\/p\u003e\n\n\u003ch2 id=\"comparison\"\u003eComparing GLP-1RA Medications\u003c\/h2\u003e\n\n\u003cp\u003eThe original article provides a comparative overview of the efficacy and adverse effects of mainstream GLP-1RA medications. The comparison covers cardiovascular benefit, renal (kidney) benefit, weight loss, patient adherence, HbA1c reduction, injection problems, gastrointestinal side effects, and antibody issues. HbA1c is a blood test that reflects average blood sugar levels over the past two to three months.\u003c\/p\u003e\n\n\u003cp\u003eIn this comparison, the \"+\" and \"−\" symbols indicate the efficacy profile or adverse effect profile of each parameter. More symbols mean greater strength or severity. More \"+\" signs indicate a greater benefit. More \"−\" signs indicate more severe side effect issues.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExenatide\u003c\/strong\u003e — cardiovascular benefit: +; renal benefit: −−; weight loss: −−; patient adherence: −; HbA1c reduction: −; injection problems: −; gastrointestinal side effects: −−; antibody issues: −−\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLixisenatide\u003c\/strong\u003e — cardiovascular benefit: +; renal benefit: −−; weight loss: −−; patient adherence: −; HbA1c reduction: −; injection problems: −; gastrointestinal side effects: −−; antibody issues: −\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOral semaglutide\u003c\/strong\u003e — cardiovascular benefit: ++; renal benefit: +; weight loss: −−; patient adherence: −−; HbA1c reduction: −; injection problems: −; gastrointestinal side effects: −−; antibody issues: −\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDulaglutide\u003c\/strong\u003e — cardiovascular benefit: ++; renal benefit: +; weight loss: ++; patient adherence: ++; HbA1c reduction: −; injection problems: −−; gastrointestinal side effects: −−; antibody issues: −\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiraglutide\u003c\/strong\u003e — cardiovascular benefit: +; renal benefit: ++; weight loss: ++; patient adherence: ++; HbA1c reduction: −−; injection problems: −; gastrointestinal side effects: −−; antibody issues: −\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExenatide extended-release\u003c\/strong\u003e — cardiovascular benefit: ++; renal benefit: ++; weight loss: −; patient adherence: −; HbA1c reduction: −; injection problems: −; gastrointestinal side effects: −; antibody issues: −\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSemaglutide (subcutaneous)\u003c\/strong\u003e — cardiovascular benefit: +++; renal benefit: +++; weight loss: +++; patient adherence: ++; HbA1c reduction: ++; injection problems: −; gastrointestinal side effects: −; antibody issues: −\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn this table, CV stands for cardiovascular, GI stands for gastrointestinal, RE stands for extended-release, and SC stands for subcutaneous administration.\u003c\/p\u003e\n\n\u003ch2 id=\"sideeffects\"\u003eSide Effects and Safety\u003c\/h2\u003e\n\n\u003cp\u003eGLP-1RAs may have side effects, including nausea, vomiting, diarrhea, and injection site reactions. These side effects are often mild and tend to improve over time. Rare but serious side effects may include pancreatitis and allergic reactions.\u003c\/p\u003e\n\n\u003cp\u003eFor albiglutide (Tanzeum), animal studies showed tumors, although it is unclear if this effect also occurs in humans. Later, the FDA added a warning about the risk of anaphylactic shock to the medication's label. Anaphylactic shock is a severe and potentially life-threatening allergic reaction. Symptoms include unease, tingling, dizziness, itching, hives, swelling, difficulty breathing, and fainting.\u003c\/p\u003e\n\n\u003cp\u003eTanzeum was discontinued by GlaxoSmithKline (GSK) in 2017, primarily due to economic factors. Despite GSK's attempts to gain a competitive edge through low pricing, Tanzeum failed to achieve sufficient market acceptance. In 2017, Tanzeum was removed from the preferred drug list of leading pharmacy benefit manager (PBM) company Express Scripts. It was replaced by Eli Lilly's Trulicity, highlighting Tanzeum's weak market presence. Moreover, this decision was part of a broad strategic reform led by GSK's new CEO Emma Walmsley. This reform aimed to refocus the company's efforts on areas with higher revenue potential.\u003c\/p\u003e\n\n\u003ch2 id=\"individual\"\u003eIndividual GLP-1RA Medications in Detail\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eExenatide.\u003c\/strong\u003e Exenatide is a medication that belongs to the class of drugs known as GLP-1RAs. It is a synthetic version of the hormone exendin-4, which is found in the saliva of the Gila monster, a venomous lizard native to the southwestern United States. Exenatide is composed of 39 amino acids and shares 53% sequence identity to human GLP-1. The second position of its N-terminus is glycine (alanine in GLP-1), which is not easily degraded by the DPP-4 enzyme. Compared with GLP-1, the C-terminus of its amino acid sequence contains 9 additional amino acid residues (PSSGAPPPS). These residues are not easily degraded by peptide chain endonucleases. Therefore, exenatide has a long half-life and strong biological activity. The average half-life of exenatide is 2.4 hours, requiring 2 to 3 injections per day.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLiraglutide.\u003c\/strong\u003e Liraglutide is a medication used to treat T2DM and obesity. In the treatment of T2DM, liraglutide helps lower blood sugar levels by increasing insulin production and reducing glucose production by the liver. It also slows stomach emptying, which helps control appetite and reduce food intake. In addition to lowering blood sugar levels, liraglutide helps reduce body weight by suppressing appetite and reducing energy intake. However, its associated costs and need for daily injections may limit its use in individuals with obesity.\u003c\/p\u003e\n\n\u003cp\u003eLiraglutide was first approved by the FDA in 2010 under the brand name Victoza for the treatment of T2DM. Since then, it has also been approved for other indications, such as chronic weight management, under the brand name Saxenda. Liraglutide has an arginine at position 34 (GLP-1(7-37) has lysine at this position), and its lysine at position 26 connects to a 16-carbon palmitic acid side chain linked by glutamic acid. Liraglutide shares 97% sequence homology with human GLP-1 and can bind to and activate GLP-1R. The elimination half-life of liraglutide is 13 hours, and only one injection per day is required.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLixisenatide.\u003c\/strong\u003e Lixisenatide was developed by Sanofi to treat T2DM. Structurally, lixisenatide is based on the exenatide structure but lacks proline at position 38. Six lysines are linked after serine at position 39. The six lysine residues increase the peptide's stability.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review shows that GLP-1RAs are not just diabetes drugs. They act on multiple body systems and may offer benefits for a wide range of conditions. For patients with type 2 diabetes, GLP-1RAs lower blood sugar without increasing the risk of hypoglycemia. This is an important safety advantage over some other diabetes medications.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with obesity, GLP-1RAs reduce body weight by suppressing appetite and reducing energy intake. Newer dual and triple agonists, such as tirzepatide and retatrutide, have shown even stronger weight loss effects in clinical trials. Tirzepatide outperformed semaglutide in phase 3 clinical trials, and retatrutide showed unprecedented weight loss effects in phase 2 clinical trials.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with cardiovascular disease, GLP-1RAs have been found to significantly reduce the risks of heart failure, atherosclerosis, and hypertension. This means that patients with both diabetes and heart conditions may gain dual benefits from these medications.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, GLP-1RAs have shown potential in slowing disease progression. For patients with inflammatory conditions such as osteoarthritis and rheumatoid arthritis, the anti-inflammatory properties of GLP-1RAs offer new hope.\u003c\/p\u003e\n\n\u003cp\u003eThe development of once-weekly and oral formulations is expected to improve patient compliance. Better compliance means patients are more likely to take their medication as prescribed, which can lead to better health outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Research\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a review, not a new clinical trial. It summarizes findings from many different studies, and those studies used different methods, different patient populations, and different timeframes. This makes direct comparisons between medications difficult.\u003c\/p\u003e\n\n\u003cp\u003eSome of the findings described in this review come from animal studies, not human studies. For example, the triple agonist's weight loss effects were shown in mice. The tumor findings for albiglutide were seen in animals, and it is unclear if this effect also occurs in humans.\u003c\/p\u003e\n\n\u003cp\u003eMany of the potential benefits of GLP-1RAs in areas such as neuroprotection, anti-infection, and cancer treatment are still being investigated. These are promising areas of research, but they are not yet proven treatments for these conditions.\u003c\/p\u003e\n\n\u003cp\u003eThe review does not provide specific numbers for many of the outcomes it describes. For example, it does not report the exact percentage of patients who experienced weight loss or the exact reduction in cardiovascular events. Patients should discuss their individual risk factors and treatment options with their healthcare provider.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you have type 2 diabetes, obesity, or cardiovascular disease, GLP-1RAs may be an option for you. Talk to your doctor about whether these medications are appropriate for your situation.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eDiscuss your full medical history with your healthcare provider, including any history of pancreatitis, kidney disease, or allergic reactions.\u003c\/li\u003e\n  \u003cli\u003eAsk about the different GLP-1RA options available, including once-weekly and oral formulations, to find the one that best fits your lifestyle.\u003c\/li\u003e\n  \u003cli\u003eBe aware of common side effects such as nausea, vomiting, and diarrhea. These often improve over time, but tell your doctor if they persist or worsen.\u003c\/li\u003e\n  \u003cli\u003eReport any signs of a serious allergic reaction immediately. These signs include difficulty breathing, swelling, itching, hives, dizziness, or fainting.\u003c\/li\u003e\n  \u003cli\u003eFollow your prescribed dosing schedule carefully. Do not change your dose without talking to your doctor first.\u003c\/li\u003e\n  \u003cli\u003eContinue with diet and exercise recommendations from your healthcare provider. GLP-1RAs are meant to be used alongside these lifestyle measures, not instead of them.\u003c\/li\u003e\n  \u003cli\u003eKeep up with regular check-ups so your doctor can monitor your blood sugar, kidney function, and overall health.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eRemember that this article summarizes research findings. It is not a substitute for personalized medical advice. Your healthcare provider can help you understand the risks and benefits of GLP-1RA therapy for your specific situation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are GLP-1 receptor agonists and how do they work?\u003c\/h3\u003e\n\u003cp\u003eGLP-1 receptor agonists are injectable medications that mimic the natural hormone GLP-1. They stimulate insulin release, suppress glucagon, slow stomach emptying, and reduce appetite through the brain. They lower blood sugar without increasing the risk of dangerously low blood sugar. They are approved as add-on therapy to diet and exercise for type 2 diabetes in adults.\u003c\/p\u003e\n\u003ch3\u003eCan GLP-1 receptor agonists help with weight loss?\u003c\/h3\u003e\n\u003cp\u003eYes, GLP-1 receptor agonists can reduce body weight by suppressing appetite and lowering energy intake. In clinical trials, newer dual and triple agonists such as tirzepatide and retatrutide have shown stronger weight loss effects. Tirzepatide outperformed semaglutide in phase 3 trials, and retatrutide showed unprecedented weight loss in phase 2 trials. However, individual results vary.\u003c\/p\u003e\n\u003ch3\u003eWhat are the common side effects of GLP-1 receptor agonists?\u003c\/h3\u003e\n\u003cp\u003eCommon side effects include nausea, vomiting, diarrhea, and injection site reactions. These are often mild and tend to improve over time. Rare but serious side effects may include pancreatitis and allergic reactions. For albiglutide, animal studies showed tumors, though it is unclear if this occurs in humans. Report any signs of a serious allergic reaction immediately.\u003c\/p\u003e\n\u003ch3\u003eAre GLP-1 receptor agonists safe for my heart and kidneys?\u003c\/h3\u003e\n\u003cp\u003eResearch shows GLP-1 receptor agonists may significantly reduce the risks of heart failure, atherosclerosis, and hypertension. Some also have renal benefits. For example, semaglutide (subcutaneous) showed strong cardiovascular and renal benefits in comparisons. However, these findings come from various studies, and individual results may differ. Discuss your heart and kidney health with your doctor.\u003c\/p\u003e\n\u003ch3\u003eHow often do I need to take GLP-1 receptor agonists?\u003c\/h3\u003e\n\u003cp\u003eDosing varies by medication. Exenatide is injected twice daily, liraglutide once daily, and dulaglutide, albiglutide, and semaglutide once weekly. Oral semaglutide is taken once daily by mouth. Researchers are developing longer-acting and oral formulations to improve convenience and compliance. Follow your prescribed schedule carefully and do not change your dose without talking to your doctor.\u003c\/p\u003e\n\u003ch3\u003eCan GLP-1 receptor agonists treat conditions other than diabetes?\u003c\/h3\u003e\n\u003cp\u003eGLP-1 receptor agonists are being studied for obesity, cardiovascular disease, non-alcoholic fatty liver disease, neurodegenerative diseases like Alzheimer's and Parkinson's, and inflammatory conditions such as osteoarthritis and rheumatoid arthritis. Some show potential in slowing disease progression, but many of these benefits are still being investigated and are not yet proven treatments. Talk to your doctor about your specific condition.\u003c\/p\u003e\n\u003ch3\u003eWhat should I discuss with my doctor before starting a GLP-1 receptor agonist?\u003c\/h3\u003e\n\u003cp\u003eDiscuss your full medical history, including any history of pancreatitis, kidney disease, or allergic reactions. Ask about different GLP-1 receptor agonist options, including once-weekly and oral formulations, to find one that fits your lifestyle. Be aware of common side effects and report any serious allergic reaction signs immediately. Continue diet and exercise as recommended. This information is not a substitute for personalized medical advice.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with type 2 diabetes or obesity on a GLP-1 receptor agonist seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help when the choice among GLP-1 receptor agonists is unclear. These medications differ in dosing, half-life, cardiovascular and kidney effects, weight loss, gastrointestinal side effects, and antibody issues, and comparisons are difficult because studies used different methods, populations, and timeframes. A second opinion may also help if you have a history of pancreatitis, kidney disease, or allergic reactions, or if you are considering once-weekly or oral formulations. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Glucagon-like peptide-1 receptor mechanisms and advances in therapy\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, and Junjie Gao\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Microsurgery on Extremities and Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Centre for Orthopaedic Research, Medical School, The University of Western Australia, Nedlands, WA, Australia\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCorresponding author:\u003c\/strong\u003e Junjie Gao (junjie.gao@shsmu.edu.cn)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Signal Transduction and Targeted Therapy (2024) 9:234\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1038\/s41392-024-01931-z\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Review Article, Open Access\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReceived:\u003c\/strong\u003e 18 February 2024; \u003cstrong\u003eRevised:\u003c\/strong\u003e 17 June 2024; \u003cstrong\u003eAccepted:\u003c\/strong\u003e 16 July 2024\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCopyright:\u003c\/strong\u003e © The Author(s) 2024\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider about your individual health conditions and treatment options.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47807393988764,"sku":null,"price":0.0,"currency_code":"RUB","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ru\/products\/glp-1-receptor-agonists-how-they-work-and-what-they-can-treat","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}